Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2022 May 15.

Published in final edited form as: J Neurol Sci. 2021 Mar 20;424:117409. doi: 10.1016/j.jns.2021.117409

Table 2.

Summary of the patients’ cohort and EPM2A/EPM2B correlations.

	EPM2A mutations (N=9)	EPM2B mutations (N=17)	p value

Gender: Male	3 (33.3%)	6 (35.3%)	1.00^a
Female	6 (66.7%)	11 (64.7%)	1.00^a

Onset: Epilepsy	3/9 (50.0%)	6/9 (42.8%)	1.00^a
Myoclonus	1/5 (16.7%)	4/5 (28.6%)
Epilepsy and myoclonus	2/6 (33.3%)	4/6 (26.6%)

	Median [1^st-3^rd q]	Median [1^st-3^rd q]
Age at disease onset (y)	13 (11–13)	14.5 (13–16) [n=16]	0.039^b
Age at last evaluation (y)	23 (18.6–24)	22.8 (19.1–31.1)	0.83^b
Follow-up duration (y)	10 (7.6–12.6)	8.9 (4.8–19.1) [n=16]	0.89^b

N = number; q = quartile; y = years.

^a

P: Fisher’s Exact test.

^b

P: Mann-Whitney U test.